• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二羰基修饰 LDL 在猴子和人类中的清除和利用。

Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans.

机构信息

Department for Free Radical Biochemistry, E.I. Chazov' National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow 121552, Russia.

Research Institute of Medical Primatology, National Research Center "Kurchatov' Institute", Sochi 354376, Russia.

出版信息

Int J Mol Sci. 2023 Jun 21;24(13):10471. doi: 10.3390/ijms241310471.

DOI:10.3390/ijms241310471
PMID:37445648
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10341789/
Abstract

The kinetics of elimination of various dicarbonyl-modified low-density lipoproteins from the bloodstream of monkeys were investigated. The low-density lipoproteins (LDL) in the monkey blood plasma were isolated by density gradient ultracentrifugation and labeled in vitro with the fluorescent dye FITC; thereupon, they were modified with different natural low molecular-weight dicarbonyls: malondialdehyde (MDA), glyoxal, or methylglyoxal. The control native FITC-labeled LDL and dicarbonyl-modified FITC-labeled LDL were injected into the monkey's ulnar vein; thereafter, blood samples were taken at fixed time intervals during 24 h. The plasma level of FITC-labeled LDL was determined with spectrofluorimetry. The study established that glyoxal- and monkeysglyoxal-labeled LDL circulated in monkey virtually at the same time as native (non-modified) LDL. In contrast, MDA-modified LDL disappeared from the blood extremely rapidly. Administration of the PCSK9 inhibitor involocumab (which increases LDL utilization) to patients with coronary heart disease (CHD) was found to significantly reduce levels of MDA-modified LDL.

摘要

研究了各种二羰基修饰的低密度脂蛋白(LDL)从猴子血液中消除的动力学。通过密度梯度超速离心从猴子血浆中分离 LDL,并在体外用荧光染料 FITC 标记;随后,用不同的天然低分子量二羰基化合物:丙二醛(MDA)、乙二醛或甲基乙二醛对其进行修饰。将对照的天然 FITC 标记 LDL 和二羰基修饰的 FITC 标记 LDL 注入猴子的尺骨静脉;此后,在 24 小时内的固定时间间隔采集血液样本。用荧光分光光度法测定血浆中 FITC 标记 LDL 的水平。研究表明,乙二醛和甲基乙二醛修饰的 LDL 在猴子体内的循环时间与天然(未修饰)LDL 几乎相同。相比之下,MDA 修饰的 LDL 从血液中迅速消失。在冠心病(CHD)患者中给予 PCSK9 抑制剂依洛尤单抗(可增加 LDL 的利用)可显著降低 MDA 修饰的 LDL 水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34eb/10341789/f73b0698de48/ijms-24-10471-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34eb/10341789/2162172f0831/ijms-24-10471-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34eb/10341789/f73b0698de48/ijms-24-10471-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34eb/10341789/2162172f0831/ijms-24-10471-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34eb/10341789/f73b0698de48/ijms-24-10471-g002.jpg

相似文献

1
Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans.二羰基修饰 LDL 在猴子和人类中的清除和利用。
Int J Mol Sci. 2023 Jun 21;24(13):10471. doi: 10.3390/ijms241310471.
2
[Elimination kinetics of carbonyl-modified low density lipoproteins from bloodstream].[血液中羰基修饰低密度脂蛋白的消除动力学]
Biomed Khim. 2020 Nov;66(6):437-443. doi: 10.18097/PBMC20206606437.
3
Dicarbonyl-Modified Low-Density Lipoproteins Are Key Inducers of LOX-1 and NOX1 Gene Expression in the Cultured Human Umbilical Vein Endotheliocytes.二羰基修饰的低密度脂蛋白是培养的人脐静脉内皮细胞中 LOX-1 和 NOX1 基因表达的关键诱导剂。
Biochemistry (Mosc). 2023 Dec;88(12):2125-2136. doi: 10.1134/S0006297923120143.
4
Malonyldialdehyde and glyoxal act differently on low-density lipoproteins and endotheliocytes.丙二醛和乙二醛对低密度脂蛋白和内皮细胞的作用不同。
Mol Cell Biochem. 2014 Nov;396(1-2):79-85. doi: 10.1007/s11010-014-2144-x. Epub 2014 Jul 27.
5
The Role of Natural Low Molecular Weight Dicarbonyls in Atherogenesis and Diabetogenesis.天然低分子量二羰基化合物在动脉粥样硬化和糖尿病发生中的作用。
Rev Cardiovasc Med. 2024 Aug 20;25(8):295. doi: 10.31083/j.rcm2508295. eCollection 2024 Aug.
6
[The role of oxidative processes in augmentation of atherogenity of low density lipoprotein particles].[氧化过程在增强低密度脂蛋白颗粒致动脉粥样硬化性中的作用]
Kardiologiia. 2012;52(6):61-6.
7
Interrelation between malonyl dialdehyde-dependent modification and cholesterol content in low-density lipoproteins.低密度脂蛋白中丙二醛依赖性修饰与胆固醇含量之间的相互关系。
Bull Exp Biol Med. 2010 Aug;149(2):184-6. doi: 10.1007/s10517-010-0903-6.
8
Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative and carbonyl stress.氧化应激和羰基应激条件下低密度脂蛋白的氧化修饰机制
Biochemistry (Mosc). 2007 Oct;72(10):1081-90. doi: 10.1134/s0006297907100069.
9
[Development of Novel Diagnostic Agents for Atherosclerosis Using Fluorescence-labeled Peptides].[利用荧光标记肽开发新型动脉粥样硬化诊断剂]
Yakugaku Zasshi. 2016;136(10):1367-1372. doi: 10.1248/yakushi.16-00080.
10
Dicarbonyl-Dependent Modification of LDL as a Key Factor of Endothelial Dysfunction and Atherosclerotic Vascular Wall Damage.二羰基依赖性低密度脂蛋白修饰作为内皮功能障碍和动脉粥样硬化血管壁损伤的关键因素
Antioxidants (Basel). 2022 Aug 12;11(8):1565. doi: 10.3390/antiox11081565.

引用本文的文献

1
The Role of Natural Low Molecular Weight Dicarbonyls in Atherogenesis and Diabetogenesis.天然低分子量二羰基化合物在动脉粥样硬化和糖尿病发生中的作用。
Rev Cardiovasc Med. 2024 Aug 20;25(8):295. doi: 10.31083/j.rcm2508295. eCollection 2024 Aug.

本文引用的文献

1
Malondialdehyde as an Important Key Factor of Molecular Mechanisms of Vascular Wall Damage under Heart Diseases Development.丙二醛作为心脏病发展中心血管壁损伤分子机制的重要关键因素。
Int J Mol Sci. 2022 Dec 21;24(1):128. doi: 10.3390/ijms24010128.
2
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.在已确诊动脉粥样硬化性心血管疾病患者中使用长效依洛尤单抗的研究
Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29.
3
Dicarbonyl-Dependent Modification of LDL as a Key Factor of Endothelial Dysfunction and Atherosclerotic Vascular Wall Damage.
二羰基依赖性低密度脂蛋白修饰作为内皮功能障碍和动脉粥样硬化血管壁损伤的关键因素
Antioxidants (Basel). 2022 Aug 12;11(8):1565. doi: 10.3390/antiox11081565.
4
PCSK9 and atherosclerosis: Looking beyond LDL regulation.PCSK9 与动脉粥样硬化:超越 LDL 调控的视角。
Eur J Clin Invest. 2021 Apr;51(4):e13459. doi: 10.1111/eci.13459. Epub 2020 Dec 3.
5
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level.依洛尤单抗对脂蛋白(a)水平升高的健康个体中脂蛋白(a)和前蛋白转化酶枯草溶菌素9的影响。
J Cardiovasc Dev Dis. 2020 Oct 15;7(4):45. doi: 10.3390/jcdd7040045.
6
Multiple rare and common variants in APOB gene locus associated with oxidatively modified low-density lipoprotein levels.载脂蛋白 B 基因座的多个罕见和常见变异与氧化修饰的低密度脂蛋白水平相关。
PLoS One. 2019 May 31;14(5):e0217620. doi: 10.1371/journal.pone.0217620. eCollection 2019.
7
Role of Ox-LDL and LOX-1 in Atherogenesis.氧化低密度脂蛋白和清道夫受体 LOX-1 在动脉粥样硬化形成中的作用。
Curr Med Chem. 2019;26(9):1693-1700. doi: 10.2174/0929867325666180508100950.
8
Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence.在动脉粥样硬化斑块中的泡沫细胞形成过程中,氧化型 LDL 的吞噬作用依赖于 PLD2-CD36 的功能相互依存。
J Leukoc Biol. 2018 May;103(5):867-883. doi: 10.1002/JLB.2A1017-407RR. Epub 2018 Apr 14.
9
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).依洛尤单抗降低低密度脂蛋白胆固醇水平及外周动脉疾病患者的结局:来自 FOURIER 试验(在高风险人群中用 PCSK9 抑制剂进行进一步心血管结局研究)的见解。
Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13.
10
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.